期刊文献+

七叶洋地黄双甙滴眼液联合复方血栓通治疗老年性黄斑变性的疗效观察 被引量:7

The clinical curative effect of stullen and compound thrombosis capsule on senile macular degeneration
下载PDF
导出
摘要 目的观察七叶洋地黄双甙滴眼液联合复方血栓通胶囊治疗老年性黄斑变性的临床疗效。方法将108例185眼老年性黄斑变性(SMD)患者分为三组。A组采用七叶洋地黄双甙滴眼液,每次1滴,滴双眼,3次/d,1个月为1疗程;B组口服复方血栓通胶囊,每次3粒,3次/d,1个月为1疗程;C组采用七叶洋地黄双甙滴眼液联合复方血栓通胶囊,用法同前。2个月后观察3组视力及黄斑水肿、出血、渗出等变化情况。结果与A和B两组相比,C组疗效更显著,其中视力最高提高0.4,一般提高0.2~0.3,视力减退者有2例3眼,视力稳定者2例3眼。结论七叶洋地黄双甙滴眼液联合复方血栓通胶囊对治疗老年性黄斑变性(SMD)有明显的疗效。 Objection To observe the clinical curative effect of StuUen and Compound thrombosis capsule on Senile macular degeneration. Methods 185 to 108 cases of Senile macular degeneration (SMD) were dividede into three groups. Group - A adopt Stullen to drip eye liquid set, 1 drops of binocnlus at every time, in every day 3 is inferior, 1 months is one course of treatment; Group -B takes the Compound thrombosis capsule 3 each time, triple in every day, 1 months is one course of treatment; Group - C adopt Stullen to ally self with the Compound thrombosis capsule, the usage ditto set. 2 months of queens observe whose sight and the yellow spot edema, bleeding, oozing and so on changes condition. Results compared with A and B two groups, the C group curative effect is more notable, sight among them improves 0.4 be taller than most, is improve 0.2 -0.3, sight retrogression person has 3 regular eyes, sight stabilizes person 3 regular eyes. Conclusion Stullen joint compound thrombosis capsule for the treatment of Senile macular degeneration (SMD) has obvious effects.
作者 钟佩 李红
出处 《临床和实验医学杂志》 2009年第3期69-69,72,共2页 Journal of Clinical and Experimental Medicine
关键词 七叶洋地黄双甙滴眼液 复方血栓通 老年性黄斑变性 疗效 Stullen Compound thrombosis capsule Senile macular degeneration (SMD) Clinical curative effect
  • 相关文献

参考文献7

二级参考文献41

  • 1Del Priore LV,Ya-Hui Kuo,Tezel TH.Age-Related changes in human RPE cell density and apoptosis proportion in situ.Invest Ophthalmol Vis Sci,2002,43:3312-3318.
  • 2Holz FG,Pauleikhoff D,Klein R,et al.Pathogenesis of lesion in late age-related macular disease.Arch Ophthalmol,2004,137:504-510.
  • 3Gilbert Grand M,Bressler NM,Brown GC.Basic and clinical science course section 12,retina and vitreous.San Francisco:American Academy of Ophthalmology,1998-1999.46-48.
  • 4Kamizuru H,Kimura H,Yasukawa T,et al.Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat.Invest Ophthalmol Vis Sci,2001,42:2664-2672.
  • 5Grunwald JE,Metelitsina TI,DuPont JC,et al.Reduced foveolar choroidal blood flow in eyes with increasing AMD severity.Invest Ophthalmol Vis Sci,2005,46:1033 1038.
  • 6Welge-Lussen UC,Fuchshofera R,Kampik A.Influence of hypoxia in the early and late changes of age related macular degeneration.Invest Ophthalmol Vis Sci,2004,45:3383.
  • 7Johnson PT,Lewis GP,Talaga KC,et al.Drusen-Associated Degeneration in the Retina.Invest Ophthalmol Vis Sci,2003,44:4481-4488.
  • 8Friedman E.Update of the vascular model of AMD.Br J Ophthalmol,2004,88:161-163.
  • 9Reme CE,Grimm C,Hafezi F,et al.Why study rod cell death in retinal degenerations and how? Doc Ophthalmol,2003,106:2529.
  • 10Owsley C,Jacksot GR,Cideciyan AV,et al.Psychophysical evidence for rod vulnerability in age-related macular degeneration.Invest Ophthalmol Vis Sci,2000,41:267-273.

共引文献82

同被引文献116

引证文献7

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部